BrainMap

Mrs. Lorelei Irina Brasoveanu

Senior researcher, PhD

Senior Researcher - INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU"

Researcher | Scientific reviewer | Other | PhD supervisor

Web of Science ResearcherID: E-7146-2019

Curriculum Vitae (06/10/2021)

Expertise & keywords

Molecular markers as predictors of treatment outcome and global prognosis in the management of differentiated thyroid carcinoma. Call name: Joint Applied Research Projects - PCCA-2011 call, Type 2
PN-II-PT-PCCA-2011-3.2-1337 2012 - 2016

Role in this project:

Coordinating institution: INSTITUTUL NATIONAL DE ENDOCRINOLOGIE "C.I.PARHON" BUCURESTI

Project partners: INSTITUTUL NATIONAL DE ENDOCRINOLOGIE "C.I.PARHON" BUCURESTI (RO); INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO); INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO); AGILROM SCIENTIFIC SRL (RO)

Affiliation: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO)

Project website: http://www.parhon.ro

Abstract:

Thyroid cancer, the most frequent endocrine malignancy, is a treatable disease if properly diagnosed. However, some cases develop aggressive disease by severe mutations or dedifferentiation, while others are diagnosed incidentally while being operated for a multinodular goiter, with microcarcinomas surrounded by non-neoplastic thyroid tissue. Risk factors, environment, family history and oncogenetic events favor or trigger this transformation. The present study will evaluate the prevalence of thyroid cancer in a prospective observational approach, involving the National Institute of Endocrinology as well as other three partners: Institute of Virology Stefan S. Nicolau, Institute of Cell Biology and Pathology Nicolae Simionescu and Agilrom Scientific SRL.

Major objective of the project: Improvement of the diagnostic and follow-up protocols for thyroid differentiated carcinoma with new markers for a better treatment outcome, prognosis and quality of life

The patients will be evaluated according to current guidelines of care. In an attempt to improve the diagnostic and treatment protocols after a detailed genomic/epigenetic approach of the cases the most significant markers will be selected. A total of 300 new cases of differentiated thyroid cancer, as well as multinodular goiter controls will be followed in a 3 years cohort, being evaluated by clinical, biochemical, pathology and advanced imaging (ultrasound and I131 gamma camera) technology, as well as routine and immunohistochemistry pathology. Genetic (genomic and tumor DNA), epigenetic and proteic markers will be evaluated on biological samples (blood and tumor tissue), and compared between the groups with different tumor pathology and expected/encountered evolution. A final practical target will be the design of a microarray chip for genetic diagnosis of thyroid cancer susceptibility. Another result will be the nucleus of thyroid cancer registry in Romania and the improvement of current diagnosis and treatment

Design and development of transport and delivery systems for new ruthenium compunds with antitumor activity Call name: Joint Applied Research Projects - PCCA-2011 call, Type 2
PN-II-PT-PCCA-2011-3.2-1454 2012 - 2016

Role in this project:

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); INSTITUTUL ONCOLOGIC PROF.DR.ALEXANDRU TRESTIOREANU BUCURESTI (RO); UNIVERSITATEA BUCURESTI (RO); INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO); PHARMA SERV INTERNATIONAL SRL (RO)

Affiliation: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO)

Project website: http://cercetare-umf.ro/uploads_ro/592/Pagina_web_136_2012-actualizata_2016.pdf

Abstract:

The proposed cooperative study is a complex interdisciplinary approach aimed at developing pharmaceutical product models with significant antitumor action and minimal side effects. During the project, three pharmaceutical systems that include some ruthenium complexes will be studied regarding solubility, capacity to transport and deliver the active substance at the final site of action, the antitumor activity and the side effects. The final scope of the project is to select the system (or systems) who best meet the requirements regarding bioavailability and pharmaco-toxicological properties for a possible inclusion in the clinical trials of the studied ruthenium complexes.

The proposed project has least three main goals. First, we want to develop pharmaceutical systems for improve the solubility of some ruthenium compounds in order to achieve a better pharmacokinetic profile for these compounds. Second, we intend to evaluate the antitumor activity of the developed systems using various cell lines from solid tumors and in vivo, comparing to cisplatin as reference substance. Third, we intend to evaluate the general toxicity of the developed systems, comparing to cisplatin. Additionally, we want to explore the possibility of development of these products as oral drugs and to establish what kind of cancer can be treated with these agents.

Identification and characterization of a subpopulation of cells with tumor stem cell properties in hepatoma and esophageal cancers correlate with the mechanisms of resistance to treatment Call name:
PNCDI II Grant 420144/2008 2008 - 2011

Role in this project: Partner team leader

Coordinating institution: INSTITUTUL ONCOLOGIC PROF.DR.ALEXANDRU TRESTIOREANU BUCURESTI

Project partners: INSTITUTUL ONCOLOGIC PROF.DR.ALEXANDRU TRESTIOREANU BUCURESTI (); INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" ()

Affiliation: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" ()

Project website:

Abstract:

“Immunogenomical study of expression and functional role of some cell adhesion molecules (CAM) associated to colorectal cancer” Call name:
PNCDI II Grant 420173 /2008 2008 - 2011

Role in this project: Project coordinator

Coordinating institution: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU"

Project partners: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" ()

Affiliation: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" ()

Project website:

Abstract:

Studies in cellular and molecular level of biological activity of curcumin in order to evaluate potential therapeutic Call name:
P-CD 77/2006 CEEX Program (Biomedical) 2006 - 2008

Role in this project: Partner team leader

Coordinating institution: UNIVERSITATEA BUCURESTI

Project partners: UNIVERSITATEA BUCURESTI (); INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (); INSTITUTUL ONCOLOGIC PROF.DR.ALEXANDRU TRESTIOREANU BUCURESTI ()

Affiliation: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" ()

Project website:

Abstract:

Modulation of expression of several biological markers of tumor progression and correlation with resistance to chemotherapy in breast and ovarian cancers Call name:
P-CD 123/2006 CEEX Program (Biomedical) 2006 - 2008

Role in this project: Project coordinator

Coordinating institution: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU"

Project partners: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" ()

Affiliation: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" ()

Project website:

Abstract:

Radiolabelled biomolecules for targeted therapy of cancer and angiogenesis inhibition Call name:
P-CD 26/2005 CEEX Program (Biomedical) 2005 - 2008

Role in this project: Partner team leader

Coordinating institution: INSTITUTUL NATIONAL DE CERCETARE - DEZVOLTARE PENTRU FIZICA SI INGINERIE NUCLEARA " HORIA HULUBEI " - IFIN - HH

Project partners: INSTITUTUL NATIONAL DE CERCETARE - DEZVOLTARE PENTRU FIZICA SI INGINERIE NUCLEARA " HORIA HULUBEI " - IFIN - HH (); INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (); INSTITUTUL ONCOLOGIC PROF.DR.ALEXANDRU TRESTIOREANU BUCURESTI ()

Affiliation: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" ()

Project website:

Abstract:

FILE DESCRIPTION	DOCUMENT
List of research grants as project coordinator or partner team leader
Significant R&D projects for enterprises, as project manager
R&D activities in enterprises
Peer-review activity for international programs/projects